VRTX · 10-Q · 2026Q2 · Full report

Geographic Market Commentary

VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 54 · Surprise 40

U.S. revenue increased 11% in the second quarter and 9% in the first half of 2026, reflecting strong patient demand, new ALYFTREK initiations, higher realized CF net prices, and contributions from CASGEVY and JOURNAVX. Ex-U.S. revenue increased 14% in the quarter and 12% in the first half, supported by strong CF performance across multiple geographies, ALYFTREK uptake, higher CASGEVY revenues and favorable foreign-exchange effects. Vertex continues to pursue country-by-country reimbursement for CF products, CASGEVY, JOURNAVX and future pipeline therapies.